325 reports of this reaction
2.7% of all LUMACAFTOR AND IVACAFTOR reports
#8 most reported adverse reaction
CYSTIC FIBROSIS is the #8 most commonly reported adverse reaction for LUMACAFTOR AND IVACAFTOR, manufactured by Vertex Pharmaceuticals Incorporated. There are 325 FDA adverse event reports linking LUMACAFTOR AND IVACAFTOR to CYSTIC FIBROSIS. This represents approximately 2.7% of all 12,020 adverse event reports for this drug.
Patients taking LUMACAFTOR AND IVACAFTOR who experience cystic fibrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYSTIC FIBROSIS is a less commonly reported adverse event for LUMACAFTOR AND IVACAFTOR, but still significant enough to appear in the safety profile.
In addition to cystic fibrosis, the following adverse reactions have been reported for LUMACAFTOR AND IVACAFTOR:
The following drugs have also been linked to cystic fibrosis in FDA adverse event reports:
CYSTIC FIBROSIS has been reported as an adverse event in 325 FDA reports for LUMACAFTOR AND IVACAFTOR. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYSTIC FIBROSIS accounts for approximately 2.7% of all adverse event reports for LUMACAFTOR AND IVACAFTOR, making it a notable side effect.
If you experience cystic fibrosis while taking LUMACAFTOR AND IVACAFTOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.